This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up

CHICAGO ( TheStreet) -- Treatment with Roche's (RHHBY) experimental GA101 -- the next-generation version of the company's blockbuster drug Rituxan -- helped elderly patients with chronic lymphocytic leukemia more than double the time before their disease worsened compared to chemotherapy. Initial data, not yet mature, also suggests GA101 may be superior to Rituxan.

Results from a pivotal phase III study of GA101 were posted in a research abstract Wednesday night ahead of a planned presentation at the American Society of Clinical Oncology (ASCO) annual meeting. Last January, Roche announced that the GA101 study had met its primary endpoint but detailed data were held for presentation at the ASCO meeting.

Roche has engineered GA101, also known as obinutuzumab, to be a more potent version of Rituxan, the company's top-selling hematological monoclonal antibody therapy with 2012 sales of approximately $7 billion. Rituxan sales, however, could start to fade in 2016 when a biosimilar version of the drug is expected to enter the market. For this reason, development and approval of GA101 has taken on some urgency for Roche in order to protect a key drug franchise.

An FDA approval approval application for GA101 in CLL was submitted earlier this year and another phase III study of the drug in non-Hodgkin's lymphoma -- where Rituxan generates the bulk of its sales -- is also underway.

In the phase III study, elderly CLL patients with other co-morbidities were randomized to treatment with GA101 plus chemotherapy, Rituxan plus chemotherapy or chemotherapy alone. In the first stage of the study, patients treated with GA101 plus chemotherapy had a median progression-free survival of 23 months (and growing because data are not yet mature) compared to 10.9 months for patients treated with chemotherapy alone.

At the time of the data cutoff, GA101 reduced the risk of disease progression in these CLL patients by 86% relative to chemotherapy. The result was statistically significant.

Seventy-five percent of CLL patients treated with GA101 reported tumor shrinkage, including 22 percent complete responses, compared to an overall response rate of 30% for chemotherapy and zero complete responses.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
RHHBY $34.25 0.00%
GILD $101.00 0.00%
PCYC $256.56 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs